Hydroxyazepanes as inhibitors of glycosidase and HIV protease

Details Hydroxyazepanes as inhibitors of glycosidase and HIV protease Hydroxyazepanes as inhibitors of glycosidase and HIV protease

1999-08-23

2002-10-08

Coleman, Brenda (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

Reexamination Certificate

active

06462193

ABSTRACT:

DESCRIPTION
Technical Field
The present invention relates to compounds that inhibit glycosidases and HIV proteases. More particularly, the present invention relates to seven-membered hydroxyiminocyclitols, also known as hydroxyazepanes, which have inhibitory activity toward glycosidases and hiv protease and to chemical and enzymatic/chemical methods for synthesizing such compounds.
BACKGROUND
Glycosidases are involved in the processing and synthesis of complex carbohydrates which are essential for various biological recognition processes. Because of their multifaceted biological importance, these enzymes are often targeted for inhibition. (Look et al.
Acc. Chem. Res.
1993, 26, 182; Winchester et al.
Glycobiology
1992, 2, 1991; Wong et al.
Angew. Chem. Int. Ed. Engl.
1995, 34, 521; Legler et al.
Adv. Carbohydr. Chem. Biochem.
1990, 48, 319; Sinnott et al.
Chem. Rev.
1990, 90, 1171; Kirby et al.
Adv. Phys. Org. Chem.
1994, 29, 87; Jacob et al.
Curr. Opin. Struct. Biol.
1995, 5, 605.
Glycosidases and aspartyl proteases share a common mechanism in catalysis, i.e. both utilize two carboxyl groups as general acid and general base in the hydrolytic reactions (Wlodawer et al.
Science
1989, 245, 616; Hyland et al.
Biochemistry
1991, 30, 8454; Reviews on the mechanisms of glycosidases: Sinnott et al.
Chem. Rev.
1990, 90, 1171; Legler et al.
Adv. Carb. Chem. Biochem.
1990, 48, 319; Withers et al.
Pure
&
Appl. Chem.
1995, 67, 1673).
Five- and six-membered azasugar families have been characterized as mimics of the transition state of the enzymatic reactions of glycosidases and aspartyl proteases. (Withers et al.
J. Am. Chem. Soc.
1988, 110, 8551; Ganem et al.
J. Am. Chem. Soc.
1991, 113, 8984; Papandreou et al.
J. Am. Chem. Soc.
1993, 115, 11682; Fotsch et al.
Tetrahedron Lett.
1994, 35, 3481; Jeong et al.
J. Am. Chem. Soc.,
1996, 118, 4227.) Five- and six-membered iminocyclitols, for example, have been used as transition-state analog inhibitors of glycosidases (Elbein et al.
Annu. Rev. Biochem.
1987, 56, 497; Wichester et al.
Glycobiology
1992, 2, 199; Look et al.
Acc. Chem. Res.
1993, 26, 182; Jacob et al.
Current Opinion in Structural Biology
1995, 5, 605) and various peptide isosteres, including those with C
2
-symmetry, have been developed as inhibitors of the HIV (Human Immunodeficiency Virus) protease (Erickson et al.
Perspectives in Drug Discovery and Design
1993, 1, 109.)
Unlike five and six-membered iminocyclitols, the biological activities of seven-membered iminocyclitols, also known as hydroxyazepanes, are largely uncharacterized. One hydroxyazepane was reported to have no inhibitory activity against &agr;-mannosidase. (Farr et al.
Tetrahedron
1994, 50, 1033.) These heterocycles are conformationally more flexible than the corresponding six- and five-membered counterparts and may adopt the half-chair or pseudo-chair structure to mimic the transition state of the enzymatic glycosidic cleavage. (Qian et al.
Bioorg. Med. Chem. Lett.
1996, 6, 1117.)
Conventional synthetic methods for producing hydroxyazepanes require lengthy linear chemical routes with multiple steps in overall low yields. (Paulsen et al.
Chem. Ber
1967, 100, 512; Poitout et al.
Tetrahedron Lett.
1994, 35, 3293; Lohray et al.
J. Org. Chem.
1995, 60, 5958; Farr et al.
Tetrahedron
1994, 50, 1033.)
What is needed is hydroxyazepanes having inhibitory activity with respect to glycosidases and aspartyl proteases and chemical or chemo/enzymatic methods for synthesizing hydroxyazepanes in high yields with a small number of synthetic steps.
SUMMARY OF THE INVENTION
One aspect of the invention is directed to methodologies for the chemical or chemo/enzymatic synthesis of seven-membered iminocyclitols which are also known as hydroxyazepanes. A series of hydroxyazepanes is obtained either by chemoenzymatic or chemical synthesis. The compounds display significant activity as glycosidase inhibitors, with K
i
values from moderate to low micromolar range. The 3-benzyl and 3,6-dibenzyl derivatives of these hydroxyazepanes, viz. compounds
60
a
,
60
b
,
64
a
,
64
b
,
65
a
, and
65
b
(FIGS.
8
and
20
), inhibit the mechanistically related HIV protease.
In a first mode, a chemo/enzymatic methodology is employed for synthesizing hydroxyazepanes. In the first step, there is an addition of (±)-3-azido-2-hydroxypropanaldehyde with dihydroxyacetone phosphate (DHAP) in the presence of a DHAP dependent aldolase to produce a 6-azido-3,4,5-trihydroxy-2-hexanone-1-phosphate intermediate. In the second step, there is an hydrolysis of the 6-azido-3,4,5-trihydroxy-2-hexanone-1-phosphate intermediate to produce a polyhydroxy 6-deoxy-6-azido ketose by treatment with acid phosphatase. In the third step, there is an isomerization of the ketose to a 6-azido-6-deoxyaldopyranose by treatment with an isomerase. The fourth and final step comprises cyclization of the pyranose to a seven membered hydroxyazepane using reductive amination conditions on the C6 azide moiety of the pyranose with hydrogen and a catalyst.
Alternative modes include several novel chemical syntheses of hydroxyazepanes which involve chemical manipulations of aldopyranoses protected as benzyl glycosides or diisopropylidene ethers. All of the chemical syntheses involve the use of a Pd-mediated reductive amination conditions for ring expansion of the six membered pyranose to form the seven membered azepane. Examples of this chemical approach show that D-galactose can be used to obtain a meso-3,4,5,6-tetrahydroxyperhydroazepine; D-mannose can be used to obtain a derivative with a C
2
symmetry axis and N-acetylglucosamine can be used to obtain a 6-acetamidoiminocyclitol.
More particularly, one mode of the invention is directed to a method for producing a tetrahydroxyazepane. In this mode, there is an initial addition reaction of 3-azido-2-hydroxypropanaldehyde with dihydroxyacetone phosphate using an aldolase for producing a 6-azido-3,4,5-trihydroxy-2-hexanone-1-phosphate intermediate with the formula:
Then the above 6-azido-3,4,5-trihydroxy-2-hexanone-1-phosphate intermediate is hydrolyzed with acid phosphatase for producing a polyhydroxy 6-deoxy-6-azido ketose intermediate with the formula:
Then the above polyhydroxy 6-deoxy-6-azido ketose intermediate is isomerized with an isomerase for producing a 6-azido-6-deoxyaldose intermediate with the formula:
Then the above 6-azido-6-deoxyaldose intermediate is cyclized using reductive amination conditions with hydrogen and a catalyst for producing the tetrahydroxyazepane with the formula:
An alternative mode of the invention is directed to another method for synthesizing a tetrahydroxyazepane. The 6-hydroxyl position of a 6-hydroxy-1,2,3,4-protected monosaccharide is activated with an activating agent for producing an activated 6-hydroxy-1,2,3,4-protected monosaccharide with the formula:
wherein R
1
is selected from the group consisting of benzyl and isopropylidene; R
2
is selected from the group consisting of tosylate and (P(Phenyl)
3
)
+
. Then the above activated 6-hydroxy-1,2,3,4-protected monosaccharide is admixed with an azide donor for producing a 6-azido-6-deoxy-1,2,3,4-protected monosaccharide with the formula:
wherein R
1
is selected from the group consisting of benzyl and isopropylidene. Then, the above protected 6-azido-6-deoxy-1,2,3,4-protected monosaccharide is deprotected with a deprotecting agent for producing a 6-azido-6-deoxysugar with the formula:
Then, the above 6-membered ring of the 6-azido-6-deoxysugar is expanded under reductive amination conditions with hydrogen and a catalyst for producing the tetrahydroxyazepane with the formula:
In a preferred mode, the 6-azido-6-deoxysugar is then converted into a 3-methoxy-tri-hydroxyazepane with additional steps. The 6-azido-6-deoxysugar is glycosylated with a glycosylating agent for producing a 6-azido-6-deoxyglycoside with the formula:
wherein R
1
is selected from the group consisting of methyl, propyl and benzyl. Then, the 3 and 4 hydroxyl positions on the above 6-azido-6-deoxyglycoside i

Affiliated with

Also associated with

Rating

Hydroxyazepanes as inhibitors of glycosidase and HIV protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxyazepanes as inhibitors of glycosidase and HIV protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyazepanes as inhibitors of glycosidase and HIV protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2926250